Please use this identifier to cite or link to this item:
https://www.um.edu.mt/library/oar/handle/123456789/49438
Title: | How does fingolimod (Gilenya®) fit in the treatment algorithm for highly active relapsing-remitting multiple sclerosis? |
Authors: | Fazekas, Franz Bajenaru, Ovidiu Berger, Thomas Hojs Fabjan, Tanja Ledinek, Alenka Horvat Jakab, Gábor Komoly, Samuel Kobys, Tetiana Kraus, Jörg Kurca, Egon Kyriakides, Theodoros Lisý, Lubomír Milanov, Ivan Nehrych, Tetyana Moskovko, Sergii Panayiotou, Panayiotis Jazbec, Saša Šega Sokolova, Larysa Taláb, Radomír Traykov, Latchezar Turcáni, Peter Vass, Karl Vella, Norbert Voloshyná, Nataliya Havrdová, Eva |
Keywords: | Multiple sclerosis -- Case studies Multiple sclerosis -- Treatment Algorithms |
Issue Date: | 2013 |
Publisher: | Frontiers Research Foundation |
Citation: | Fazekas, F., Bajenaru, O., Berger, T., Hojs Fabjan, T., Horvat Ledinek, A., Jakab, G., ... & Kyriakides, T. (2013). How does fingolimod (Gilenya®) fit in the treatment algorithm for highly active relapsing-remitting multiple sclerosis?. Frontiers in Neurology, 4(10), 1-14. |
Abstract: | Multiple sclerosis (MS) is a neurological disorder characterized by inflammatory demyelination and neurodegeneration in the central nervous system. Until recently, disease-modifying treatment was based on agents requiring parenteral delivery, thus limiting long-term compliance. Basic treatments such as beta-interferon provide only moderate efficacy, and although therapies for second-line treatment and highly active MS are more effective, they are associated with potentially severe side effects. Fingolimod (Gilenya®) is the first oral treatment of MS and has recently been approved as single disease-modifying therapy in highly active relapsing-remitting multiple sclerosis (RRMS) for adult patients with high disease activity despite basic treatment (beta-interferon) and for treatment-naïve patients with rapidly evolving severe RRMS. At a scientific meeting that took place in Vienna on November 18th, 2011, experts from ten Central and Eastern European countries discussed the clinical benefits and potential risks of fingolimod for MS, suggested how the new therapy fits within the current treatment algorithm and provided expert opinion for the selection and management of patients. |
URI: | https://www.um.edu.mt/library/oar/handle/123456789/49438 |
Appears in Collections: | Scholarly Works - FacM&SMed |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
How_does_fingolimod_Gilenya_fit_in_the_treatment_algorithm_for_highly_active_relapsing_remitting_multiple_sclerosis.pdf | 2.22 MB | Adobe PDF | View/Open |
Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.